Aim Leukocytes have been implicated in restenosis following percutaneous transluminal coronary angioplasty. We investigated the link between the activated status of circulating neutrophils and restenosis after angioplasty.
Introduction
The technique of percutaneous transluminal coronary angioplasty has undergone tremendous improvements. However, the recurrence of coronary stenosis is still a major problem in interventional cardiology. Some years ago, it became clear that differences in vascular remodelling play a major role in the restenotic process after balloon angioplasty [1] [2] [3] [4] .
Specific therapies to reduce the unsolved issue of restenosis after percutaneous coronary interventions requires an understanding of the biochemical mechanism of the restenotic process. Therefore, the contribution of leukocytes to the restenotic process has been investigated [5] [6] [7] [8] . Recently, it has been suggested that granulocytes do not contribute to the occurrence of intimal hyperplasia [9] , confirming the findings of Rogers et al. about the central role of monocytes in that process [10] . Further, we have found that expression of the CD66 receptor by neutrophils pre-procedure is associated with a better angiographic prognosis after balloon angioplasty [5] . While many activation markers were studied, the activation status of the neutrophil relevant for the angiographic outcome was best characterized by the magnitude of CD66 expression [5] . Although inflammation leading to weaker adventitial layers may induce positive remodelling in experimental models [11, 12] , the exact mechanism (neointimal formation or remodelling) involved in the potential beneficial effect of neutrophils on restenosis is still unknown.
The neutrophil CD66 antigen, differently from the CD11b/CD18 receptor, is exclusively expressed by granulocytes and is considered to be an activation marker [13] . The CD66 family members expressed by granulocytes have been found to be associated intracellularly with tyrosine kinases such as Lyn and Hck that mediate signal transduction from the receptor [14] . It is not known if CD66 could serve as a marker for a subpopulation of neutrophils that play a specific role in the mechanism of restenosis. Neutrophils express four different CD66 members belonging to a group of highly glycosylated proteins of the carcinoembryonic antigen family, i.e. CD66a, Cd66b (formerly known as CD67), CD66c, and CD66d [15] . CD66a and CD66b are stored in the secondary granules, while CD66c is present in the primary granules of the neutrophil [16] [17] [18] . Upon ligation, these molecules may regulate CD11b/CD18-mediated adhesion without the functional activation of that receptor and potentiate the production of reactive oxygen species [19] [20] [21] . To our knowledge, the variation in CD66 expression in humans has not yet been extensively studied.
The aims of the present study were first to validate the unexpected finding of our pilot study [5] concerning the inverse association between relative late lumen loss and the pre-procedural expression of the neutrophil activation marker CD66, and finally to discern in which of the two components of restenosis (neointimal hyperplasia and/or remodelling) do activated neutrophils, expressing the specific receptor CD66, contribute. Thus, we evaluated the link between the expression of CD66 before the procedure and late luminal renarrowing in an independent group of balloon angioplasty patients, and in a population treated with stent implantation.
Methods
This study consists of a cohort of 108 consecutive patients successfully treated with elective balloon angioplasty (n=44) or stent implantation (n=64) at the Thoraxcenter. All patients were treated for single-vessel, short (<20 mm) and de novo lesions located in native coronary arteries. Patients treated during the acute phase of myocardial infarction as well as those with in-hospital complications after the procedure (myocardial infarction, repeat revascularization or subacute thrombotic occlusion) were excluded. The protocol was approved by the Medical Ethical Committee of the Erasmus University Hospital, Rotterdam, and all patients provided written inform consent.
Protocol
Sheaths (7 or 8 French) were inserted into the arterial and venous femoral vessels. Thirty millilitres of blood were collected from the venous sheath immediately before treatment, anticoagulated with 0·2% EDTA, and kept at 4 C. The method of revascularization, balloon angioplasty or stenting was based on operator's preference as well as the type of stent to be implanted. The devices (balloon or stent) were sized according to the reference vessel diameter and lesion length. The procedures were performed according to standard clinical practice, with high-pressure (at least 12 atmospheres) post-stenting balloon inflation. All patients received aspirin (250 mg . day 1 ) at least 24 h before the procedure, whereas stented patients also received ticlopidine (250 mg twice a day, maintained for a period of 30 days after the procedure).
Quantitative coronary angiography
Coronary angiograms were obtained in each patient preand post-procedure and at the 6-month follow-up. All angiograms were analysed using the CAAS system (Pie Medical BV, Maastricht, The Netherlands) according to previously described methodology [22] . Measurements were performed in multiple (d2) matched angiographic views after intracoronary nitrates had been administered. The contrast-free guiding catheter was selected for calibration and the interpolated reference vessel diameter at the computer-defined minimal lumen site was automatically calculated. All measurements were performed off-line by an independent core laboratory (Cardialysis BV, Rotterdam, The Netherlands) unaware of the biochemical analysis results.
Lumen change, as evinced by continuous angiographic criteria, has been used considerably in clinical trials and more closely reflects the magnitude of reactive intimal hyperplasia, than dichotomous variables such as >50% diameter stenosis [23, 24] . Thus, in accordance with our pilot study, we chose relative late loss as the dependent variable. Relative late loss was calculated as absolute late loss (minimal lumen diameter post minus minimal lumen diameter at follow-up) divided by the pre-procedure reference diameter. By taking the reference vessel size into account, this parameter may be better than absolute late loss in addressing the impact of vascular lumen reduction. For comparison, we used other angiographic variables, such as the loss index (absolute late loss divided by minimal lumen diameter post) and net gain (minimal lumen diameter at follow up -pre-procedure minimal lumen diameter) as well.
Reagents
The monoclonal antibody (mAb) used in the flow cytometric analysis of membrane antigen expression was mAb CLB-gran10 directed against CD66acde (the Central Laboratory for Blood transfusion, Amsterdam, The Netherlands).
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Flow cytometric analysis of membrane antigens
To prevent any staining procedure related activation the leukocytes were kept on ice during the entire procedure to inhibit their normal metabolic processes. The reagents were endotoxin free. Erythrocytes in the blood sample were lysed with a sterile ammonium chloride solution consisting of 155 mM NH 4 Cl, 10 mM NaHCO 3 and 0·1 mM EDTA at 4 C. This procedure does not alter the expression of CD66(b) or other membrane activation markers of the neutrophil [25] . BD . This procedure took 3-4 h from the time of collection until fixation. Until the cells could be analysed (<1 week), they were stored at 4 C in the dark. The binding of mAb to the cell surface was quantified by fluorescence-activated cell sorting (FACStar, Becton Dickinson, Etten-Leur, The Netherlands). Five thousand events were acquired after live gating of the neutrophils with the use of forward vs sideward scatter. Antigen expression is presented as specific median fluorescence intensity.
Statistical Analysis
Variation in duplicate measurements (intra-assay variation) did not exceed 10%. Univariate linear regression analysis was performed to determine the association between relative late loss after treatment and each biological, clinical, angiographic, and procedure-related variable. In order to establish independent risk factors, each variable that proved to be statistically significant (P<0·05) was entered in a stepwise multivariate linear regression model with 'P' values for inclusion and elimination set at 0·05 and 0·10. We also performed separate analyses for each therapeutic population, balloon angioplasty and stent. The correlation between pre-procedure variables (clinical, angiographic) and the level of CD66 expression by neutrophils was also tested using univariate linear regression.
Results
Baseline characteristics are shown in Table 1 . Pre-, postand follow-up angiographic results are summarized in Table 2 . The expression of the neutrophil membrane receptor CD66 ranged from 0 to 22·42 of mean fluorescence intensity (average value of 6·4 3·6). No relationship between the biological markers and clinical (including unstable angina) or angiographic pre-procedure variables was found in our study. The mean CD66 expression was 5·5 2·1 of mean fluorescence intensity in the stent group and 7·6 4·7 of mean fluorescence intensity in the balloon angioplasty group.
Predictors of relative late loss in the total population (n=108)
We identified several univariate predictors of relative late loss: expression of CD66, the use of stents, minimal lumen diameter post, and absolute gain (Table 3) . No clinical variable was correlated with relative late loss. By stepwise linear regression, only absolute gain and CD66 remained as independent predictors of relative late loss (Table 3) . Absolute gain showed a direct correlation with increased relative late loss, whereas the expression of CD66 showed an inverse association with relative late loss.
Predictors of relative late loss after balloon angioplasty
In a separate analysis, we found some univariate predictors of relative late loss in the population treated with balloon angioplasty (n=44): expression of CD66, target site in the left anterior descending coronary artery and diabetes (Table 3 ). In the multivariate regression model, the target site located in the left anterior descending coronary artery and the expression of CD66 remained as independent predictors of relative late loss. Treatment of the left anterior descending coronary artery was directly related to relative late loss after balloon angioplasty, whereas the expression of CD66 remained inversely 
Predictors of relative late loss after stenting
No biological risk factor was associated with relative late loss in the stent population (n=64). Scatterplots showing the link between the expression of the membrane antigen CD66 and relative late loss in the balloon angioplasty and stented patients are illustrated in Fig. 1 . Two angiographic variables were independent predictors of relative late loss: pre-procedure reference vessel diameter and acute gain (Table 3) .
Discussion
The present investigation corroborates the results of the pilot study [5] in showing that the activation status of circulating neutrophils, as demonstrated by the expression of the CD66 antigen, is inversely related to late coronary lumen loss after percutaneous coronary intervention. The standardized regression coefficients ( ) of CD66 were similar in both the present study (balloon angioplasty group) and the pilot investigation [5] ( 0·49 and 0·47, respectively). However, the expression of this antigen did not show any relationship to vessel renarrowing after stenting.
This could be relevant in understanding the role of neutrophils in preventing luminal renarrowing after angioplasty, since stents almost abolish the contribution of remodelling to the restenotic process and have been considered as a pure model with which to investigate neointimal hyperplasia [26, 27] . Thus, the finding that activated neutrophils expressing the CD66 antigen may prevent vessel renarrowing after balloon angioplasty, but not after stenting, may encourage us to speculate on whether circulating phagocytes play a role in the mechanism of vessel remodelling after injury. Indeed, inflammatory mediators have already been shown to promote vessel enlargement in experimental models [11, 12] . However, the limitations of angiography, as regards directly assessing vascular remodelling after angioplasty, should be taken into account before drawing any definitive conclusion. Further, the study population was not randomly divided into plain balloon angioplasty or stenting, which may have introduced an unwanted source of bias.
In the process of geometric remodelling of the vessel upon vascular injury, alterations in the extracellular matrix metabolism, specifically collagen redistribution, appear to be important factors [28] . In restenotic lesions, total collagen content and collagen organization are significantly less in comparison to non-restenotic vessels. While smooth muscle cells and fibroblasts produce various matrix proteins upon stimulation by cytokines secreted by monocytes in the lesion, these proteins, in their turn, could be degraded by matrix metalloproteinases. Neutrophils can release a soluble factor that activates endothelial cell matrix metalloproteinase-2 [29] . On this basis, neutrophils would play a negative role in the remodelling process. On the other hand, while the exact function of CD66 is currently unknown, it is noteworthy that gonococci expressing distinctly opaque outer membrane proteins enter granulocytes via this receptor without stimulating their bactericidal repertoire and using phagocytes as an intracellular niche to survive [31] . Can this particular subpopulation of neutrophils prevent the change in phenotype of the myofibroblasts and smooth muscle cells, or the activation of the metalloproteinase cascade? Presently, no adequate mechanistic answer can be given. However, if CD66-expressing neutrophils accumulate at the site of injury and this receptor is stimulated properly, its distinct signalling pathway [30] may lead to beneficial action, as indicated by this study. Clearly, the underlying mechanism of the beneficial effect of CD66-expressing neutrophils on late lumen renarrowing after balloon angioplasty requires further investigation. Monocytes appear to be an important contributing factor to neointimal formation after vascular injury. Accordingly, the administration of antibodies to the CD11b or CD18 receptor subunits was shown to prevent intimal hyperplasia upon angioplasty or stent implantation in experimental animal models [10, 32] . However, granulocytes also express the CD11b/CD18 or Mac-1 adhesion receptor and are recruited early to the traumatized vascular wall [33] [34] [35] [36] [37] . Thus any intervention directed to the Mac-1 receptor will prevent the entry of both monocytes and granulocytes into the lesion site, in fact revealing the net effect of the separate actions of each cell type. In a number of experimental models of vascular injury, in which neutrophils predominated in the lesion, the administration of monoclonal CD18 antibodies have failed to inhibit neointimal formation [9, 38, 39] . This indicates that neutrophils may not be involved in this process. However, prevention of the local accumulation of neutrophils by using antibodies to block the granulocyte-specific CD66 receptor should demonstrate that the action of granulocytes does not contribute to, or even compensate for, the stimulatory effect of monocytes on intimal hyperplasia.
Other well-known angiographic risk-factors, such as the target lesion located at the left anterior descending coronary artery in the balloon population and reference vessel diameter and acute lumen gain in the stent group, were retained in the multivariate model. The left anterior descending coronary artery has been associated with a higher restenosis rate after angioplasty [40] . Greater acute gain has already been shown to stimulate proliferative responses [40] , which may reflect the higher degree of vessel wall injury in this situation [40, 41] . Finally, the reference diameter was inversely associated with late lumen renarrowing, which may highlight the importance of vessel size in the outcome of patients treated with stents [42] . However, it should be considered that, by definition, vessel size is inversely correlated with relative lumen loss (relative lumen loss=late loss divided by reference diameter).
Taken together, this study confirms that preprocedure activation of circulating neutrophils expressing the CD66 antigen exert a protective influence on late vessel renarrowing after percutaneous coronary intervention and further suggests that these leukocytes may be implicated in the mechanism of vascular remodelling. 
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